Cardiopulmonary bypass primes polymorphonuclear leukocytes

Jess D. Schwartz, Peter Shamamian, Daniel S. Schwartz, Eugene A. Grossi, Chad E. Jacobs, Federico Steiner, Peter C. Minneci, F. Gregory Baumann, Stephen B. Colvin, Aubrey C. Galloway

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Polymorphonuclear leukocyte (PMN) superoxide (· O2/-) production has been implicated in the pathogenesis of cardiopulmonary bypass (CPB)-related end organ injury. PMN 'priming' has been described as an event which enhances the release of · O2/- following a second, activating insult. We hypothesized that PMN priming occurs during CBP and is temporally related to the plasma level of complement (C3a), interleukin (IL)-6, and IL-8. PMNs were isolated from 10 CPB patients pre-bypass (preCPB), 5 min after protamine administration (PROT), and at 6 and 24 h post-CPB. PMN · O2- production was measured by a cytochrome c reduction assay in the presence or absence of either phorbol 12-myristate-13-acetate (PMA, 0.4 μg/ml) or N-formyl- methionyl-leucyl-phenylalanine (FMLP, 1 μM) and also after priming with 2000 nM platelet-activating factor (PAF) followed by activation with either PMA or FMLP. Plasma levels of C3a, IL-6, and IL-8 were determined by enzyme-linked immunosorbent assay. PMA-activated PMN ·O2/- production was significantly elevated at 6 h post-CPB compared to preCPB levels (11.04 ± 0.9 vs 7.62 ± 0.57, P = 0.009), indicating that CPB is associated with in vivo PMN priming. When PMNs were primed in vitro with PAF and then activated with PMA or FMLP, · O2/- release at 6 h post-CPB was also significantly greater than pre- CPB levels (16.04 ± 0.74 vs 12.2 ± 0.92, P = 0.038; and 17.33 ± 1.38 vs 13.33 ± 1.35, P < 0.05), indicating that CPB acts synergistically with PAF to prime PMNs. Levels of C3a rose significantly over pro-CPB levels at PROT (P = 0.001), and IL-6 and IL-8 rose over pre-CPB levels at 6 h post-CPB (P = 0.01 and P = 0.006, respectively). These findings demonstrate that CPB not only directly primes PMNs, but also potentiates priming of PMNs by PAF. This 'primed' PMN state, which coincided with the increased plasma levels of inflammatory mediators, may suggest a mechanism of predisposition to organ dysfunction following CPB.

Original languageEnglish (US)
Pages (from-to)177-182
Number of pages6
JournalJournal of Surgical Research
Volume75
Issue number2
DOIs
StatePublished - Mar 1998
Externally publishedYes

Fingerprint

Cardiopulmonary Bypass
Neutrophils
Platelet Activating Factor
Interleukin-8
Interleukin-6
Protamines
Complement C3a
N-Formylmethionine Leucyl-Phenylalanine
Cytochromes c
Superoxides
Acetates
Enzyme-Linked Immunosorbent Assay

Keywords

  • Complement
  • Cytokines
  • Neutrophils
  • Priming
  • Superoxide

ASJC Scopus subject areas

  • Surgery

Cite this

Schwartz, J. D., Shamamian, P., Schwartz, D. S., Grossi, E. A., Jacobs, C. E., Steiner, F., ... Galloway, A. C. (1998). Cardiopulmonary bypass primes polymorphonuclear leukocytes. Journal of Surgical Research, 75(2), 177-182. https://doi.org/10.1006/jsre.1997.5287

Cardiopulmonary bypass primes polymorphonuclear leukocytes. / Schwartz, Jess D.; Shamamian, Peter; Schwartz, Daniel S.; Grossi, Eugene A.; Jacobs, Chad E.; Steiner, Federico; Minneci, Peter C.; Baumann, F. Gregory; Colvin, Stephen B.; Galloway, Aubrey C.

In: Journal of Surgical Research, Vol. 75, No. 2, 03.1998, p. 177-182.

Research output: Contribution to journalArticle

Schwartz, JD, Shamamian, P, Schwartz, DS, Grossi, EA, Jacobs, CE, Steiner, F, Minneci, PC, Baumann, FG, Colvin, SB & Galloway, AC 1998, 'Cardiopulmonary bypass primes polymorphonuclear leukocytes', Journal of Surgical Research, vol. 75, no. 2, pp. 177-182. https://doi.org/10.1006/jsre.1997.5287
Schwartz JD, Shamamian P, Schwartz DS, Grossi EA, Jacobs CE, Steiner F et al. Cardiopulmonary bypass primes polymorphonuclear leukocytes. Journal of Surgical Research. 1998 Mar;75(2):177-182. https://doi.org/10.1006/jsre.1997.5287
Schwartz, Jess D. ; Shamamian, Peter ; Schwartz, Daniel S. ; Grossi, Eugene A. ; Jacobs, Chad E. ; Steiner, Federico ; Minneci, Peter C. ; Baumann, F. Gregory ; Colvin, Stephen B. ; Galloway, Aubrey C. / Cardiopulmonary bypass primes polymorphonuclear leukocytes. In: Journal of Surgical Research. 1998 ; Vol. 75, No. 2. pp. 177-182.
@article{357db332a1b74e278387f07e2ea61859,
title = "Cardiopulmonary bypass primes polymorphonuclear leukocytes",
abstract = "Polymorphonuclear leukocyte (PMN) superoxide (· O2/-) production has been implicated in the pathogenesis of cardiopulmonary bypass (CPB)-related end organ injury. PMN 'priming' has been described as an event which enhances the release of · O2/- following a second, activating insult. We hypothesized that PMN priming occurs during CBP and is temporally related to the plasma level of complement (C3a), interleukin (IL)-6, and IL-8. PMNs were isolated from 10 CPB patients pre-bypass (preCPB), 5 min after protamine administration (PROT), and at 6 and 24 h post-CPB. PMN · O2- production was measured by a cytochrome c reduction assay in the presence or absence of either phorbol 12-myristate-13-acetate (PMA, 0.4 μg/ml) or N-formyl- methionyl-leucyl-phenylalanine (FMLP, 1 μM) and also after priming with 2000 nM platelet-activating factor (PAF) followed by activation with either PMA or FMLP. Plasma levels of C3a, IL-6, and IL-8 were determined by enzyme-linked immunosorbent assay. PMA-activated PMN ·O2/- production was significantly elevated at 6 h post-CPB compared to preCPB levels (11.04 ± 0.9 vs 7.62 ± 0.57, P = 0.009), indicating that CPB is associated with in vivo PMN priming. When PMNs were primed in vitro with PAF and then activated with PMA or FMLP, · O2/- release at 6 h post-CPB was also significantly greater than pre- CPB levels (16.04 ± 0.74 vs 12.2 ± 0.92, P = 0.038; and 17.33 ± 1.38 vs 13.33 ± 1.35, P < 0.05), indicating that CPB acts synergistically with PAF to prime PMNs. Levels of C3a rose significantly over pro-CPB levels at PROT (P = 0.001), and IL-6 and IL-8 rose over pre-CPB levels at 6 h post-CPB (P = 0.01 and P = 0.006, respectively). These findings demonstrate that CPB not only directly primes PMNs, but also potentiates priming of PMNs by PAF. This 'primed' PMN state, which coincided with the increased plasma levels of inflammatory mediators, may suggest a mechanism of predisposition to organ dysfunction following CPB.",
keywords = "Complement, Cytokines, Neutrophils, Priming, Superoxide",
author = "Schwartz, {Jess D.} and Peter Shamamian and Schwartz, {Daniel S.} and Grossi, {Eugene A.} and Jacobs, {Chad E.} and Federico Steiner and Minneci, {Peter C.} and Baumann, {F. Gregory} and Colvin, {Stephen B.} and Galloway, {Aubrey C.}",
year = "1998",
month = "3",
doi = "10.1006/jsre.1997.5287",
language = "English (US)",
volume = "75",
pages = "177--182",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Cardiopulmonary bypass primes polymorphonuclear leukocytes

AU - Schwartz, Jess D.

AU - Shamamian, Peter

AU - Schwartz, Daniel S.

AU - Grossi, Eugene A.

AU - Jacobs, Chad E.

AU - Steiner, Federico

AU - Minneci, Peter C.

AU - Baumann, F. Gregory

AU - Colvin, Stephen B.

AU - Galloway, Aubrey C.

PY - 1998/3

Y1 - 1998/3

N2 - Polymorphonuclear leukocyte (PMN) superoxide (· O2/-) production has been implicated in the pathogenesis of cardiopulmonary bypass (CPB)-related end organ injury. PMN 'priming' has been described as an event which enhances the release of · O2/- following a second, activating insult. We hypothesized that PMN priming occurs during CBP and is temporally related to the plasma level of complement (C3a), interleukin (IL)-6, and IL-8. PMNs were isolated from 10 CPB patients pre-bypass (preCPB), 5 min after protamine administration (PROT), and at 6 and 24 h post-CPB. PMN · O2- production was measured by a cytochrome c reduction assay in the presence or absence of either phorbol 12-myristate-13-acetate (PMA, 0.4 μg/ml) or N-formyl- methionyl-leucyl-phenylalanine (FMLP, 1 μM) and also after priming with 2000 nM platelet-activating factor (PAF) followed by activation with either PMA or FMLP. Plasma levels of C3a, IL-6, and IL-8 were determined by enzyme-linked immunosorbent assay. PMA-activated PMN ·O2/- production was significantly elevated at 6 h post-CPB compared to preCPB levels (11.04 ± 0.9 vs 7.62 ± 0.57, P = 0.009), indicating that CPB is associated with in vivo PMN priming. When PMNs were primed in vitro with PAF and then activated with PMA or FMLP, · O2/- release at 6 h post-CPB was also significantly greater than pre- CPB levels (16.04 ± 0.74 vs 12.2 ± 0.92, P = 0.038; and 17.33 ± 1.38 vs 13.33 ± 1.35, P < 0.05), indicating that CPB acts synergistically with PAF to prime PMNs. Levels of C3a rose significantly over pro-CPB levels at PROT (P = 0.001), and IL-6 and IL-8 rose over pre-CPB levels at 6 h post-CPB (P = 0.01 and P = 0.006, respectively). These findings demonstrate that CPB not only directly primes PMNs, but also potentiates priming of PMNs by PAF. This 'primed' PMN state, which coincided with the increased plasma levels of inflammatory mediators, may suggest a mechanism of predisposition to organ dysfunction following CPB.

AB - Polymorphonuclear leukocyte (PMN) superoxide (· O2/-) production has been implicated in the pathogenesis of cardiopulmonary bypass (CPB)-related end organ injury. PMN 'priming' has been described as an event which enhances the release of · O2/- following a second, activating insult. We hypothesized that PMN priming occurs during CBP and is temporally related to the plasma level of complement (C3a), interleukin (IL)-6, and IL-8. PMNs were isolated from 10 CPB patients pre-bypass (preCPB), 5 min after protamine administration (PROT), and at 6 and 24 h post-CPB. PMN · O2- production was measured by a cytochrome c reduction assay in the presence or absence of either phorbol 12-myristate-13-acetate (PMA, 0.4 μg/ml) or N-formyl- methionyl-leucyl-phenylalanine (FMLP, 1 μM) and also after priming with 2000 nM platelet-activating factor (PAF) followed by activation with either PMA or FMLP. Plasma levels of C3a, IL-6, and IL-8 were determined by enzyme-linked immunosorbent assay. PMA-activated PMN ·O2/- production was significantly elevated at 6 h post-CPB compared to preCPB levels (11.04 ± 0.9 vs 7.62 ± 0.57, P = 0.009), indicating that CPB is associated with in vivo PMN priming. When PMNs were primed in vitro with PAF and then activated with PMA or FMLP, · O2/- release at 6 h post-CPB was also significantly greater than pre- CPB levels (16.04 ± 0.74 vs 12.2 ± 0.92, P = 0.038; and 17.33 ± 1.38 vs 13.33 ± 1.35, P < 0.05), indicating that CPB acts synergistically with PAF to prime PMNs. Levels of C3a rose significantly over pro-CPB levels at PROT (P = 0.001), and IL-6 and IL-8 rose over pre-CPB levels at 6 h post-CPB (P = 0.01 and P = 0.006, respectively). These findings demonstrate that CPB not only directly primes PMNs, but also potentiates priming of PMNs by PAF. This 'primed' PMN state, which coincided with the increased plasma levels of inflammatory mediators, may suggest a mechanism of predisposition to organ dysfunction following CPB.

KW - Complement

KW - Cytokines

KW - Neutrophils

KW - Priming

KW - Superoxide

UR - http://www.scopus.com/inward/record.url?scp=0031744436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031744436&partnerID=8YFLogxK

U2 - 10.1006/jsre.1997.5287

DO - 10.1006/jsre.1997.5287

M3 - Article

C2 - 9655092

AN - SCOPUS:0031744436

VL - 75

SP - 177

EP - 182

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 2

ER -